Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Cash from Financing Activities: 2010-2025

Historic Cash from Financing Activities for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Sep 2025 value amounting to $1.8 million.

  • Lineage Cell Therapeutics' Cash from Financing Activities rose 61233.33% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.3 million, marking a year-over-year increase of 100.60%. This contributed to the annual value of $35.9 million for FY2024, which is 458.26% up from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Cash from Financing Activities stood at $1.8 million for Q3 2025, which was up 697.39% from -$307,000 recorded in Q2 2025.
  • Lineage Cell Therapeutics' Cash from Financing Activities' 5-year high stood at $21.7 million during Q4 2024, with a 5-year trough of -$307,000 in Q2 2025.
  • Its 3-year average for Cash from Financing Activities is $4.4 million, with a median of $807,000 in 2023.
  • Per our database at Business Quant, Lineage Cell Therapeutics' Cash from Financing Activities surged by 1,402,000.00% in 2024 and then crashed by 392.38% in 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' Cash from Financing Activities (Quarterly) stood at $954,000 in 2021, then slumped by 87.21% to $122,000 in 2022, then crashed by 110.66% to -$13,000 in 2023, then spiked by 167,284.62% to $21.7 million in 2024, then soared by 61,233.33% to $1.8 million in 2025.
  • Its last three reported values are $1.8 million in Q3 2025, -$307,000 for Q2 2025, and $5.0 million during Q1 2025.